Simian (gorilla) adenovirus or adenoviral vectors and methods of use
The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.
1. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence that is at least 97% identical to SEQ ID NO: 1,
(b) a nucleic acid sequence that is at least 97.5% identical to SEQ ID NO: 2,
(c) a nucleic acid sequence that is at least 84.44% identical to SEQ ID NO: 3,
(d) a nucleic acid sequence that is at least 96% identical to SEQ ID NO: 4, and
(e) a nucleic acid sequence that is at least 96% identical to SEQ ID NO: 5.
2. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence that is at least 98.4% identical to SEQ ID NO: 6,
(b) a nucleic acid sequence that is at least 99.01% identical to SEQ ID NO: 7,
(c) a nucleic acid sequence that is at least 97.08% identical to SEQ ID NO: 8,
(d) a nucleic acid sequence that is at least 96.52% identical to SEQ ID NO: 9, and
(e) a nucleic acid sequence that is at least 98.49% identical to SEQ ID NO: 10.
3. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence comprising at least 121 contiguous nucleotides of SEQ ID NO: 6,
(b) a nucleic acid sequence comprising at least 462 contiguous nucleotides of SEQ ID NO: 7,
(c) a nucleic acid sequence comprising at least 234 contiguous nucleotides of SEQ ID NO: 8,
(d) a nucleic acid sequence comprising at least 606 contiguous nucleotides of SEQ ID NO: 9, and
(e) a nucleic acid sequence comprising at least 188 contiguous nucleotides of SEQ ID NO: 10.
4. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the amino acid sequences selected from the group consisting of:
(a) an amino acid sequence that is at least 93% identical to SEQ ID NO: 11,
(b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 12,
(c) an amino acid sequence that is at least 80% identical to SEQ ID NO: 13,
(d) an amino acid sequence that is at least 97.56% identical to SEQ ID NO: 14, and
(e) an amino acid sequence that is at least 88% identical to SEQ ID NO: 15.
5. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence encoding an amino acid sequence that is at least 93% identical to SEQ ID NO: 11,
(b) a nucleic acid sequence encoding an amino acid sequence that is at least 95% identical to SEQ ID NO: 12,
(c) a nucleic acid sequence encoding an amino acid sequence that is at least 80% identical to SEQ ID NO: 13,
(d) a nucleic acid sequence encoding an amino acid sequence that is at least 97.56% identical to SEQ ID NO: 14, and
(e) a nucleic acid sequence encoding an amino acid sequence that is at least 88% identical to SEQ ID NO: 15.
6. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the amino acid sequences selected from the group consisting of:
(a) an amino acid sequence that is at least 99% identical to SEQ ID NO: 16,
(b) an amino acid sequence that is at least 97.8% identical to SEQ ID NO: 18,
(c) an amino acid sequence that is at least 99.41% identical to SEQ ID NO: 19, and
(d) an amino acid sequence that is at least 99.2% identical to SEQ ID NO: 20.
7. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence encoding an amino acid sequence that is at least 99% identical to SEQ ID NO: 16,
(b) a nucleic acid sequence encoding an amino acid sequence that is at least 99.5% identical to SEQ ID NO: 17,
(c) a nucleic acid sequence encoding an amino acid sequence that is at least 97.8% identical to SEQ ID NO: 18,
(d) a nucleic acid sequence encoding an amino acid sequence that is at least 99.41% identical to SEQ ID NO: 19, and
(e) a nucleic acid sequence encoding an amino acid sequence that is at least 99.2% identical to SEQ ID NO: 20.
8. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the amino acid sequences selected from the group consisting of:
(a) an amino acid sequence comprising at least 89 contiguous amino acid residues of SEQ ID NO: 16,
(b) an amino acid sequence comprising at least 247 contiguous amino acid residues of SEQ ID NO: 18,
(c) an amino acid sequence comprising at least 230 contiguous amino acid residues of SEQ ID NO: 19, and
(d) an amino acid sequence comprising at least 231 contiguous amino acid residues of SEQ ID NO: 20.
9. A method of prophylactically or therapeutically treating a disease or infection in a mammal comprising administering to the mammal an adenovirus or adenoviral vector comprising a non-native nucleic acid sequence and one or more of the nucleic acid sequences selected from the group consisting of:
(a) a nucleic acid sequence encoding an amino acid sequence comprising at least 89 contiguous amino acid residues of SEQ ID NO: 16,
(b) a nucleic acid sequence encoding an amino acid sequence comprising at least 286 contiguous amino acid residues of SEQ ID NO: 17,
(c) a nucleic acid sequence encoding an amino acid sequence comprising at least 247 contiguous amino acid residues of SEQ ID NO: 18,
(d) a nucleic acid sequence encoding an amino acid sequence comprising at least 230 contiguous amino acid residues of SEQ ID NO: 19, and
(e) a nucleic acid sequence encoding an amino acid sequence comprising at least 231 contiguous amino acid residues of SEQ ID NO: 20.
10. The method of claim 1 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
11. The method of claim 1 , wherein the adenovirus or adenoviral vector is formulated in a composition further comprising a pharmaceutically acceptable carrier.
12. The method of claim 1 , wherein the non-native nucleic acid sequence encodes a cytokine, toxin, tumor suppressor protein, growth factor, hormone, receptor, mitogen, immunoglobulin, neuropeptide, neurotransmitter, enzyme, or antigen of a pathogen.
13. The method of claim 2 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
14. The method of claim 2 , wherein the adenovirus or adenoviral vector is formulated in a composition further comprising a pharmaceutically acceptable carrier.
15. The method of claim 2 , wherein the non-native nucleic acid sequence encodes a cytokine, toxin, tumor suppressor protein, growth factor, hormone, receptor, mitogen, immunoglobulin, neuropeptide, neurotransmitter, enzyme, or antigen of a pathogen.
16. The method of claim 4 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
17. The method of claim 4 , wherein the adenovirus or adenoviral vector is formulated in a composition further comprising a pharmaceutically acceptable carrier.
18. The method of claim 4 , wherein the non-native nucleic acid sequence encodes a cytokine, toxin, tumor suppressor protein, growth factor, hormone, receptor, mitogen, immunoglobulin, neuropeptide, neurotransmitter, enzyme, or antigen of a pathogen.
19. The method of claim 5 , wherein the adenovirus or adenoviral vector requires complementation of a deficiency in one or more early regions of the adenoviral genome for propagation and does not require complementation of any other deficiency of the adenoviral genome for propagation.
20. The method of claim 5 , wherein the adenovirus or adenoviral vector is formulated in a composition further comprising a pharmaceutically acceptable carrier.
21. The method of claim 5 , wherein the non-native nucleic acid sequence encodes a cytokine, toxin, tumor suppressor protein, growth factor, hormone, receptor, mitogen, immunoglobulin, neuropeptide, neurotransmitter, enzyme, or antigen of a pathogen.